Your Health, We Care

Home > Photo Wall > Honor and qualification

​ Production approval for Asciminib

Release date: 2024-07-10 15:26:44     Recommended: 187

10L1034_23 阿西米尼 批文_00.jpg

SCEMBLIX Aximenib is a kinase inhibitor suitable for Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) that has previously received two or more tyrosine kinase inhibitors (TKIs) and is in the chronic phase (CP). This indication has been approved under accelerated approval based on major molecular reactions (MMR). Ph+CML in CP with T315I mutation.

Company News

Research News

Drug news